ArticleBriefings in bioinformatics2025
TCRdesign: an antigen-specific generative language model for de novo design of T-cell receptors.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Disentangling Heterogeneous Molecular Networks for Multi-Omics-Driven Cancer Driver Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Structural T-Cell Receptor Analysis in the Age of Machine Learning.Immunological reviews · 2026Review
- Natural products targeting cytokine-regulated SASP inflammation networks in Ovarian cancer: Implications on immune escape and molecular resistance.Inflammopharmacology · 2026Review
- Integrating lncRNA data for prediction of miRNA-disease association using network fusion and matrix completion.Journal of computer-aided molecular design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
T-cell receptors (TCR), which are heterodimers of $\alpha $ and $\beta $ chains that recognize foreign antigens, are of great significance to current immunotherapy. Although artificial intelligence (AI) has explosively accelerated de novo protein design, the challenge of therapeutic TCR design has been overlooked by most researchers. Existing TCR engineering relies heavily on isolating antigen-specific TCRs from tumor tissues, which requires a large amount of labor resources and wet experimental verification. To mitigate this issue, we present TCRdesign, a pretrained generative protein language model (PLM) for the de novo design of artificial TCR $\beta $-chain complementarity-determining region 3 sequences conditioned on antigen-binding specificity (BS). In parallel, we develop a high-accuracy binding predictor (TCRBinder) that couples paired $\alpha $/$\beta $ chain information with antigen sequences to assess BS. Our in silico comparisons demonstrate that (i) TCRdesign surpasses state-of-the-art baselines in generating antigen-specific TCR sequences. The model leverages paired-chain coherence to refine amino-acid level interaction patterns. (ii) TCRdesign-generated TCR sequences exhibit better antigen binding capability to diverse oncogenic hotspots compared with natural counterparts. (iii) TCRdesign inherits the intrinsic properties of large PLMs, enabling effectively identify the determinant residues in TCR-antigen binding, which enhances its interpretability. These results highlight the significant capability of TCRdesign in understanding and generating TCR sequences with an antigen-specific interaction pattern, charting a versatile path toward AI-driven T-cell engineering for precision immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.